tiprankstipranks
Oculis Holding Ag (DE:CR5)
NASDAQ:CR5
Germany Market
CR5
Oculis Holding
RESEARCH TOOLSreports

Oculis Holding (CR5) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

CR5 Analyst Ratings

Strong Buy
10Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Oculis
Holding
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CR5 Stock 12 Month Forecast

Average Price Target

€33.52
▲(52.35% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Oculis Holding in the last 3 months. The average price target is €33.52 with a high forecast of €46.38 and a low forecast of €20.13. The average price target represents a 52.35% change from the last price of €22.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"€10","47":"€47","19.25":"€19.25","28.5":"€28.5","37.75":"€37.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":46.38040335,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€46.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33.516404685,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€33.52</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.12734485,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€20.13</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,19.25,28.5,37.75,47],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.55,14.229261796153846,16.90852359230769,19.58778538846154,22.267047184615386,24.94630898076923,27.625570776923077,30.304832573076922,32.98409436923077,35.66335616538461,38.34261796153846,41.021879757692304,43.701141553846156,{"y":46.38040335,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.55,13.239723437307692,14.929446874615385,16.619170311923078,18.30889374923077,19.99861718653846,21.688340623846152,23.378064061153847,25.067787498461538,26.75751093576923,28.44723437307692,30.136957810384615,31.826681247692306,{"y":33.516404685,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.55,12.209795757692309,12.869591515384617,13.529387273076924,14.189183030769232,14.84897878846154,15.508774546153846,16.168570303846153,16.82836606153846,17.48816181923077,18.147957576923076,18.807753334615384,19.467549092307692,{"y":20.12734485,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.65,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.1,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.35,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.8,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.9,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.8,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.5,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.6,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.55,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€46.38Average Price Target€33.52Lowest Price Target€20.13
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DE:CR5
Yi Chen
H.C. Wainwright
H.C. Wainwright
€22.75
Buy
3.42%
Upside
Reiterated
06/11/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Autolus Therapeutics (NASDAQ: AUTL), Galmed Pharmaceuticals (NASDAQ: GLMD) and Oculis Holding (NASDAQ: OCS)
LifeSci Capital Analyst forecast on DE:CR5
Patrick Dolezal
LifeSci Capital
LifeSci Capital
€56.88→€39.38
Buy
79.00%
Upside
Reiterated
06/06/26
Analysts Offer Insights on Healthcare Companies: Olema Pharmaceuticals (NASDAQ: OLMA), Jade Biosciences (NASDAQ: JBIO) and Oculis Holding (NASDAQ: OCS)
J.P. Morgan Analyst forecast on DE:CR5
Tessa Romero
J.P. Morgan
J.P. Morgan
€36.75→€20.13
Buy
-8.51%
Downside
Reiterated
06/03/26
J.P. Morgan Reaffirms Their Buy Rating on Oculis Holding (OCS)
Leerink Partners Analyst forecast on DE:CR5
Unknown Analyst
Leerink Partners
Not Ranked
Leerink Partners
€43.76→€35
Buy
59.11%
Upside
Reiterated
06/02/26
Oculis Holding (OCS) Gets a Buy from Leerink Partners
Guggenheim Analyst forecast on DE:CR5
Yatin Suneja
Guggenheim
Guggenheim
€65.63→€39.38
Buy
79.00%
Upside
Reiterated
06/01/26
Oculis price target lowered to $45 from $75 at GuggenheimOculis price target lowered to $45 from $75 at Guggenheim
Bank of America Securities Analyst forecast on DE:CR5
Jason Gerberry
Bank of America Securities
Bank of America Securities
€38.5→€30.63
Buy
39.22%
Upside
Reiterated
06/01/26
Oculis price target lowered to $35 from $44 at BofAOculis price target lowered to $35 from $44 at BofA
Stifel Nicolaus Analyst forecast on DE:CR5
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
€43.76→€35
Buy
59.11%
Upside
Reiterated
06/01/26
Oculis price target lowered to $40 from $50 at StifelOculis price target lowered to $40 from $50 at Stifel
Needham Analyst forecast on DE:CR5
Serge Belanger
Needham
Needham
€40.25→€33.25
Buy
51.15%
Upside
Reiterated
06/01/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT), Oculis Holding (NASDAQ: OCS) and Cogent Biosciences (NASDAQ: COGT)
Robert W. Baird Analyst forecast on DE:CR5
Colleen M. Kusy
Robert W. Baird
Robert W. Baird
€42.88→€33.25
Buy
51.15%
Upside
Reiterated
06/01/26
Oculis price target lowered to $38 from $49 at BairdOculis price target lowered to $38 from $49 at Baird
Chardan Capital Analyst forecast on DE:CR5
Daniil Gataulin
Chardan Capital
Chardan Capital
€46.38
Buy
110.82%
Upside
Reiterated
05/12/26
Oculis Holding (OCS) Gets a Buy from Chardan Capital
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DE:CR5
Yi Chen
H.C. Wainwright
H.C. Wainwright
€22.75
Buy
3.42%
Upside
Reiterated
06/11/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Autolus Therapeutics (NASDAQ: AUTL), Galmed Pharmaceuticals (NASDAQ: GLMD) and Oculis Holding (NASDAQ: OCS)
LifeSci Capital Analyst forecast on DE:CR5
Patrick Dolezal
LifeSci Capital
LifeSci Capital
€56.88→€39.38
Buy
79.00%
Upside
Reiterated
06/06/26
Analysts Offer Insights on Healthcare Companies: Olema Pharmaceuticals (NASDAQ: OLMA), Jade Biosciences (NASDAQ: JBIO) and Oculis Holding (NASDAQ: OCS)
J.P. Morgan Analyst forecast on DE:CR5
Tessa Romero
J.P. Morgan
J.P. Morgan
€36.75→€20.13
Buy
-8.51%
Downside
Reiterated
06/03/26
J.P. Morgan Reaffirms Their Buy Rating on Oculis Holding (OCS)
Leerink Partners Analyst forecast on DE:CR5
Unknown Analyst
Leerink Partners
Not Ranked
Leerink Partners
€43.76→€35
Buy
59.11%
Upside
Reiterated
06/02/26
Oculis Holding (OCS) Gets a Buy from Leerink Partners
Guggenheim Analyst forecast on DE:CR5
Yatin Suneja
Guggenheim
Guggenheim
€65.63→€39.38
Buy
79.00%
Upside
Reiterated
06/01/26
Oculis price target lowered to $45 from $75 at GuggenheimOculis price target lowered to $45 from $75 at Guggenheim
Bank of America Securities Analyst forecast on DE:CR5
Jason Gerberry
Bank of America Securities
Bank of America Securities
€38.5→€30.63
Buy
39.22%
Upside
Reiterated
06/01/26
Oculis price target lowered to $35 from $44 at BofAOculis price target lowered to $35 from $44 at BofA
Stifel Nicolaus Analyst forecast on DE:CR5
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
€43.76→€35
Buy
59.11%
Upside
Reiterated
06/01/26
Oculis price target lowered to $40 from $50 at StifelOculis price target lowered to $40 from $50 at Stifel
Needham Analyst forecast on DE:CR5
Serge Belanger
Needham
Needham
€40.25→€33.25
Buy
51.15%
Upside
Reiterated
06/01/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT), Oculis Holding (NASDAQ: OCS) and Cogent Biosciences (NASDAQ: COGT)
Robert W. Baird Analyst forecast on DE:CR5
Colleen M. Kusy
Robert W. Baird
Robert W. Baird
€42.88→€33.25
Buy
51.15%
Upside
Reiterated
06/01/26
Oculis price target lowered to $38 from $49 at BairdOculis price target lowered to $38 from $49 at Baird
Chardan Capital Analyst forecast on DE:CR5
Daniil Gataulin
Chardan Capital
Chardan Capital
€46.38
Buy
110.82%
Upside
Reiterated
05/12/26
Oculis Holding (OCS) Gets a Buy from Chardan Capital
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BBOTBridgeBio Oncology Therapeutics
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Oculis Holding

3 Months
Yi ChenH.C. Wainwright
Success Rate
13/22 ratings generated profit
59%
Average Return
+2.02%
Copying Yi Chen's trades and holding each position for 3 Months would result in 59.09% of your transactions generating a profit, with an average return of +2.02% per trade.
1 Year
Colleen M. KusyRobert W. Baird
Success Rate
10/13 ratings generated profit
77%
Average Return
+31.73%
Copying Colleen M. Kusy's trades and holding each position for 1 Year would result in 76.92% of your transactions generating a profit, with an average return of +31.73% per trade.
2 Years
Colleen M. KusyRobert W. Baird
Success Rate
9/13 ratings generated profit
69%
Average Return
+57.99%
Copying Colleen M. Kusy's trades and holding each position for 2 Years would result in 69.23% of your transactions generating a profit, with an average return of +57.99% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CR5 Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
6
5
13
25
23
Buy
2
4
8
6
4
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
8
9
21
31
27
In the current month, CR5 has received 27 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CR5 average Analyst price target in the past 3 months is 33.52.
Each month's total comprises the sum of three months' worth of ratings.

CR5 Financial Forecast

CR5 Earnings Forecast

Next quarter’s earnings estimate for CR5 is -€0.43 with a range of -€0.49 to -€0.28. The previous quarter’s EPS was -€0.53. CR5 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year CR5 has Performed in-line its overall industry.
Next quarter’s earnings estimate for CR5 is -€0.43 with a range of -€0.49 to -€0.28. The previous quarter’s EPS was -€0.53. CR5 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year CR5 has Performed in-line its overall industry.
No data currently available

CR5 Sales Forecast

Next quarter’s sales forecast for CR5 is €204.87K with a range of €0.00 to €325.20K. The previous quarter’s sales results were €0.00. CR5 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year CR5 has Performed in-line its overall industry.
Next quarter’s sales forecast for CR5 is €204.87K with a range of €0.00 to €325.20K. The previous quarter’s sales results were €0.00. CR5 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year CR5 has Performed in-line its overall industry.

CR5 Stock Forecast FAQ

What is DE:CR5’s average 12-month price target, according to analysts?
Based on analyst ratings, Oculis Holding Ag’s 12-month average price target is 33.52.
    What is DE:CR5’s upside potential, based on the analysts’ average price target?
    Oculis Holding Ag has 52.35% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Oculis Holding Ag a Buy, Sell or Hold?
          Oculis Holding Ag has a consensus rating of Strong Buy, which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Oculis Holding Ag’s share price target?
            The average share price target for Oculis Holding Ag is 33.52. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €46.38 ,and the lowest forecast is €20.13. The average share price target represents 52.35% Increase from the current price of €22.
              What do analysts say about Oculis Holding Ag?
              Oculis Holding Ag’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of Oculis Holding Ag?
                To buy shares of DE:CR5, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.